HUTCHMED to Announce 2023 Final Results
01 Februar 2024 - 9:30AM
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)
will be announcing its final results for the year ended December
31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern
Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm
Hong Kong Time (HKT).
Analysts and investors are invited to join a
conference call and audio webcast presentation with Q&A,
conducted by HUTCHMED management.
The English conference call and audio webcast
will take place at 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on
Wednesday, February 28, 2024. In addition to the usual English
webcast, there will also be a Chinese (Putonghua) webcast at 7:30
pm EST / 12:30 am GMT / 8:30 am HKT on Thursday, February 29, 2024.
Both webcasts will be available live via the company website at
www.hutch-med.com/event/. The presentation will be available for
downloading before the conference call begins. Details of the
conference call dial-in will be provided in the financial results
announcement and on the company website. A replay will also be
available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an
innovative, commercial-stage, biopharmaceutical company. It is
committed to the discovery and global development and
commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. It has
approximately 5,000 personnel across all its companies, at the
center of which is a team of about 1,800 in oncology/immunology.
Since inception it has focused on bringing cancer drug candidates
from in-house discovery to patients around the world, with its
first three medicines marketed in China, the first of which is also
marketed in the U.S. For more information, please visit:
www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries |
+852 2121 8200 /
ir@hutch-med.com |
|
|
Media Enquiries |
|
Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
/HUTCHMED@fticonsulting.com |
Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com |
|
|
Nominated Advisor |
|
Atholl Tweedie / Freddy Crossley / Daphne Zhang,
Panmure Gordon |
+44 20 7886 2500 |
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
Von Mai 2023 bis Mai 2024